Imara

Zahlen für 2021

• keine Umsätze
  
• Verlust 51 Mio. $
  
• Cash 90 Mio. $
  
• MK 29 Mio. $
  

"The Company currently expects that its full-year 2022 research and development expenses will range between $60 million and $65 million and that its full-year 2022 general and administrative expenses will range between $13 million and $15 million. The Company expects that its cash, cash equivalents and investments as of December 31, 2021, will be sufficient to enable it to fund its planned operations substantially through the first quarter of 2023."

https://ir.imaratx.com/news-releases/news-release-details/imara-reports-full-year-2021-financial-results-and-business

Die Pipeline sieht ziemlich dünn aus:

-Added clinical indication for tovinontrine to include the treatment of HFpEF;
anticipate first subject dosing in Phase 2 trial in second quarter of 2022

- Expanded pipeline with addition of IMR-261, an oral, clinic-ready Nrf2 activator
with potential indications in hemoglobin and iron overload disorders

Weiterentwicklung von IMR-687 wird nicht fortgesetzt

• nach schwachen Phase 2b Studienergebnissen in der Zwischenanalyse
  
  • betroffen sind die Ardent Studie (SCD)
    
  • und die Forte Studie (beta-thalassemia)
    

https://www.fiercebiotech.com/biotech/imara-flunks-phase-2b-trials-sickle-cell-and-thalassemia-wiping-out-clinical-pipeline

Zahlen für Q3/21

• keine Umsätze
  
• Verlust 14 Mio. $
  
• Cash 103 Mio. $
  
• Mk 38 Mio. $
  

https://ir.imaratx.com/news-releases/news-release-details/imara-reports-third-quarter-2021-financial-results-and-business

zuletzt zwei Insider-Käufe:

https://www.gurufocus.com/stock/IMRA/insider?search=imara